Sonali Biligiri
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1245611805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,741 and has fallen 99.4% since, to $16 in 2023.
Across 128 payments — averaging $30.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$743
- Novo Nordisk$704
- Sanofi-aventis U.S. LLC$259
- Daiichi Sankyo Inc.$243
- AstraZeneca$234
- Abbott$233
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,941100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $743 |
| Novo Nordisk | 20 | $704 |
| Sanofi-aventis U.S. LLC | 6 | $259 |
| Daiichi Sankyo Inc. | 3 | $243 |
| AstraZeneca | 9 | $234 |
| Abbott | 12 | $233 |
| AbbVie | 10 | $227 |
| Insulet Corporation | 2 | $166 |
| Lilly USA, LLC | 9 | $166 |
| Dexcom, Inc. | 3 | $133 |
| Corcept Therapeutics | 5 | $102 |
| Pfizer | 4 | $98 |
| Boehringer Ingelheim | 2 | $97 |
| Lifescan, Inc. | 4 | $82 |
| Sunovion Pharmaceuticals Inc. | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 3 | $61 |
| Recordati_rare_diseases_inc. | 1 | $55 |
| Amarin Pharma, Inc. | 3 | $50 |
| Ultragenyx Pharmaceutical Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Merck | 2 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Bayer | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$375
- RYBELSUS$251
- INJECTAFER$160
- Prolia$123
- SOLIQUA 100/33$110
- DEXCOM G6 TRANSMITTER$106
- EVENITY$106
- FARXIGA$105
How this compares
$3,953 in reported general payments places this provider in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Monika ShirodkarPhiladelphia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.